Industry-ready, DISTRIBUTED LEDGER TECH (DLT)-based platform
for high-quality, compliant
health care data management

Designed by Swiss life science, banking, and data privacy know-how

Why anything

Centred around the individual, considered key element to Digital Health
Take down intra- and interorganisational barriers to realize effective product/service development and delivery
Ultra-innovative Distributed Ledger Technology (DLT) for required data security and quality

Why now

The life science continuum experiences growing challenges around digitalization (data acquisition, management, usage)
It spans regulatory, privacy, quality, and cyber security aspects
The industry’s fragmentation furthermore leads to stagnation and exploding care costs

Why us

Citizen centric & controlled
Data self-curation, Subsidiarity Curation™
Post-quantum computer safe, Cellular-Protective Data Structure™
Global cross-organizational compliance management
OOTB transaction handling at industrial scale

Who benefits

Patients – receive more effective treatments
Individuals – stay healthy by personalized prevention
Care industry – reengineer/improve data-driven service delivery processes
Pharma industry – improve R&D, product efficacy, and compliance
Society/Public – reduce health care costs

ONEBIO Digital Medical Ledger Platform (ODML)

Proprietary, industry-grade Distributed Ledger Technology
  • no heavy additional investment needs for preparing classic blockchain distributions
  • no limitations on block and file size, industry-ready transaction processing, ultra secure
Decentralized SPOHD platform (Single Point of Medical Data),
  • patented built-in subsidiarity principle for data self-curation
  • continuously truthful data for fuelling data-driven health care processes
Dynamic regulatory compliance
  • patented built-in compliance engine for cross-organisational data portability
  • no outbound tokenization, no attached financial regulatory risk
E2E data protection
  • from Edge to Analytics, proprietary next-generation quantum-compute safe low-footprint tech
  • native on-chain/off-chain transaction security through Cellular-Protective Data Structure
System-wide identity
  • E2E verification and regulation-compliant authentication
Micro-service architecture
  • cloud-native (SaaS), built for global scale, big data and AI

Our data management apps

Mobile – Citizen (Patient) Data Portfolio

Tablet – Care taker Management Dashboard

Web – Care taker Management Dashboard

Our roadmap


Partnership with BlackBerry

The firm said in a press release that it would use its "carrier-grade network operation center" (NOC) to support the digital ledger, which would be developed by biotech incubator ONEBIO. It would specifically be used to securely store data from patients, labs and monitors. Read More

BlackBerry plans medical platform

BlackBerry, the software company and former maker of an eponymous line of mobile phones, announced Thursday its plans for a new blockchain platform aimed at storing and sharing medical data. Read More

BlackBerry and EoT

BlackBerry Brings its EoT Vision to Healthcare to Improve Patient Outcomes. Company announces new partnerships, customers, and blockchain solution for the ultra-secure sharing of data among all healthcare 'things' with BlackBerry Spark. Read More

Management Team


Bruno Ehrler / CEO

Industrial engineer and entrepreneur with long experience in several industries & startups.


Bruno Odermatt / CFO

Certified Public Accountant, former KPMG executive, founder/partner at Value Solutions Group with long track record in several startup exits.


Christian Dinten / CTO

Industrial engineer with extensive experience in healthcare, pharma, IT software industries, innovation management, industrialization, automation and building a Digital Ledger startup.


Sascha Sandi / COO

Serial Entrepreneur / Expert in IT infrastructure & Hosting.


Dr. Hendrik Ludolph / CDO

IT expert with strong business experience from the corporate software industry / technical specialization: data management and analytics, systems integration.



Kuno Bürge

Blockchain Entrepreneur and industrial software executive.


Antonio Ornelas

Life Science, eHealt, Molecular Diagnostic and Personalized Medicine expert.


Prof. Ove Andersen MD, PhD

Internist, Associate Professor at Copenhagen University and Head of Clinical Research Centre at Hvidovre Copenhagen University Hospital.


Georgios Georgopoulos

Physicist, business developer with long and successful track record in sales and marketing in the life sciences industry.


Regula Müller

Bioanalytical Analyst, Chief Laboratory.


Prof. Dr. Torsten Schwede

Expert and Professor for Bioinformatics, University of Basel & SIB Swiss Institute of Bioinformatics.


Otto Skolling

Business Development executive, Former VP of BD at Karolinska Development and more than 20 year of experience in medtech, biotech and pharma.


Daniel Hagemeier

Serial Entrepreneur / Expert in IT infrastructure & Hosting. Lecturer for computer science.


Dr. Mettine Bos

Assistant Professor at the Dept. of Thrombosis and Hemostasis.

Bildschirmfoto 2020-04-03 um 11.57.04

Yannick Scheidel

Experienced, multi-industry Strategy, Marketing and Sales Advisors | Former Top-Tier Strategy Consultant.

Bildschirmfoto 2018-06-04 um 11.00.50

Norbert Farkas

Life Science Expert with solid track record in Pharma, Vaccines and Diagnostic.


Visit Our Office

ONEBIO, Platz 4, 6039 Root D4, Switzerland

Call Our Office

+41 41 541 92 00

Get in touch

Disclaimer & Confidentiality

This document and the information contained in this document is strictly confidential. This document contains information that is proprietary to ONEBIO AG (ONEBIO) and its affiliates. You agree to not disclose this document or any of the information contained therein to any third party without the express prior consent of ONEBIO. Any distribution or dissemination of this document or the information contained therein without express permission of ONEBIO is strictly prohibited. This document and the information contained in this document may only be used by you to consider a business relationship with ONEBIO. Any other use of this document or the information contained therein without the express permission of ONEBIO is strictly prohibited. This document contains forward-looking statements, which include statements related to future business or financial performance, future events or future developments. In addition, representatives of ONEBIO may from time to time make oral forward-looking statements. Such statements are based on the current expectations, projections, estimates and assumptions of ONEBIO‘s management. Such statements are subject to a number of risks, uncertainties and factors, which could cause actual results to differ materially from those anticipated. Such statements are beyond ONEBIO’s control but are based on ONEBIO management’s beliefs, as well as on assumptions made by and information available to management at the time of preparation of this document and involve significant subjective judgments. Actual results, performance or achievements may differ materially from these expectations, projections, estimates or assumptions. Accordingly, no representations are made as to their attainability. ONEBIO neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. Except where otherwise indicated, this document speaks only as the date hereof.